CClinicalTrials.gg
AvailableNCT05592028Updated Oct 24, 2022

High Intensity Focused Ultrasound for X-linked Dystonia-parkinsonism

An expanded access record providing transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy in X-Linked Dystonia Parkinsonism, sponsored by University of the Philippines Manila - Philippine General Hospital. Available at 1 site in Philippines. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-24.

Sponsored by University of the Philippines Manila - Philippine General Hospital · Expanded access

Study type
Expanded access
Access type
Individual patients · Intermediate-size population · Treatment IND/protocol
Ages
18 Years and older
Sex
Male
01

Study summary

X-linked dystonia-parkinsonism (XDP) is a rare, X-linked, adult-onset, and progressive movement disorder seen almost exclusively in men from Panay Island in the Philippines. The disease is associated with mutations involving the DYT3/TAF1 gene, and all the cases described so far have been linked to Filipino ancestry. Although XDP is very rare globally, the prevalence is 5.74 per 100,000 individuals in Panay Island and 0.31 per 100,000 in the Philippines as a whole. Majority of patients (95%) were males, and the mean age of onset was 39 years. The mean duration of illness was 16 years, and the mean age of death was 55.6 years.

Read the detailed description

To determine the outcomes of MRgFUS pallidothalamic tractotomy on adult XDP patients at the Philippine General Hospital.

This is a prospective study that aims to determine the outcomes of MRgFUS pallidothalamic tractotomy (both unilateral and bilateral) on adult XDP patients at the Philippine General Hospital.

No sample size will be determined a priori. The study will be conducted over a period of five years, and all eligible patients may be invited to join the study during this period.

The procedure will be performed inside the MRI suite, using a 1.5 Tesla MRI system (GE Optima MR450, USA) and the ExAblate Neuro device (InSightec, Haifa, Israel) to deliver the focused ultrasound. The patient's head will be shaved and immobilized using a stereotactic frame under local anesthesia. An elastic diaphragm will be attached to the patient's head and connected to the ultrasound transducer,8 and the patient will be positioned inside the bore of the MRI. A reference MRI scan will be performed to position the transducer to the target, after which the MRI images (T1-weighted axial and T2-weighted axial/coronal MRI at 1 mm slices) will be fused to the preoperative CT scan for the skull-correction algorithm.8 Stereotactic treatment planning will then be performed to target the pallidothalamic tract. It is usually located at the midcommisural line (0 to 1.0 mm posterior) in the anterior-posterior direction, 8-10 mm lateral to the intercommisural line in the mediolateral direction, 0-1.5 mm inferior to the intercommisural line in the dorsoventral direction, and 6.5-7.5 mm to the thalamo-ventricular border.7 The lesion will be made 3 mm lateral to the mamillo-thalamic tract and superior and medial to the medial subthalamic nucleus.9,11,12 Once the target is set, a series of low-power sonications producing temperatures between 40-45oC and lasting 10-20 seconds will be performed.8 Clinical assessment for tremor suppression and treatment side effects will be made after each sonication,8 and definitive non-reversible thermal ablation will be performed only at the setting wherein the patient experiences tremor reduction or suppression with no adverse effects.9 The final sonication temperature usually ranges between 55-63oC.8 After the treatment, the stereotactic frame will be removed and the patient will be monitored in the hospital overnight.

The patients will be assessed within 24 hours of treatment then asked to follow up with the movement disorder neurologist (RDJ) at 2 weeks, 3 months, 6 months, 9 months, and 12 months post-treatment through a clinic visit. Video recording will be taken on initial visit and at each follow up visit. Another blinded assessor will score the videos of the patients. The outcome will be assessed using the XDP-Movement Disorder Society of the Philippines (XDP-MDSP) Scale at each visit, and comparing it to the pre-treatment baseline, as well as using the XDP Clinical and Functional Staging. The pre- and post-treatment BFMDRS and UPDRS scores will also be obtained.

For bilateral MRgFUS tractotomy, the contralateral lesion will be done at least 6 months after the first procedure, provided that there are no serious adverse effects from the first PTT lesioning.

Demographic, clinical, treatment-related, and outcome data of all study patients will be collected prospectively by the investigators throughout the duration of the study.

02

Conditions studied

  • X-Linked Dystonia Parkinsonism

Keywords

  • High intensity focused ultrasound
  • pallidothalamic tractotomy
  • transcranial MR-guided focused ultrasound
03

In context

Dystonia

319 studies on the registry are indexed under Dystonia; 56 are open to participants now.

Browse Dystonia studies →

Lead sponsor

University of the Philippines Manila - Philippine General Hospital is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • 18 years old and above
  • have been diagnosed with XDP and confirmed by genetic testing
  • have a skull density ratio (SDR) of >/= 0.35 on CT scan
  • have psychiatric and medical clearance
  • have passed the neurocognitive test
  • have undergone MRgFUS pallidothalamic tractomy, either unilateral or bilateral,

Exclusion criteria

Exclusion Criteria:

  • patients aged less than 18 years old
  • patients who have movement disorders other than XDP
  • patients with abnormal neuroimaging findings that would preclude MRgFUS lesioning
  • Skull SDR \< 0.35
  • patients with medical contraindications
  • patients who did not fulfill the inclusion criteria
05

Access details

Study type
Expanded access
Access type
Individual patients · Intermediate-size population · Treatment IND/protocol

Available treatment

  • Devicetranscranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy

    XDP patients will receive unilateral or bilateral transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy.

06

Where to request access

1 of 1 sites recruiting
  • Philippine General Hospital
    Manila, 1000, Philippines
    Available
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT05592028
Lead sponsor
University of the Philippines Manila - Philippine General Hospital
Responsible party
Roland Dominic G. Jamora (Associate Professor, University of the Philippines Manila - Philippine General Hospital) — Principal investigator
First posted
Oct 24, 2022
Last update
Oct 24, 2022

Study contacts

Roland Dominic G Jamora, MD, PhD
Contact
rgjamora@up.edu.ph
+63 2 85242338
Kathleen Joy O Khu, MD
Contact
kokhu@up.edu.ph
+63 2 85242338
Roland Dominic G Jamora, MD, PhD
principal investigator · Department of Neurosciences, University of the Philippines Manila
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion